Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>
Companies Commented On
- AtriCure Inc.
- Endologix Inc.
- HeartWare Inc.
- Novadaq Technologies Inc.
- Sunshine Heart Inc.
- Thoratec Corp.
- Vascular Solutions Inc.
Jason Mills is managing director at Canaccord Genuity. He joined Canaccord from First Albany Capital, where he was managing director and senior analyst covering the medical devices sector with a specific focus on the areas of cardiovascular disease, ophthalmology and sleep disorders. Mills previously served as a vice president and senior research analyst with Thomas Weisel Partners, where he covered companies in the ophthalmology and sports medicine/arthroscopy sectors. He holds a Master of Sports Administration from Ohio University and a Bachelor of Arts in economics from Yale University.
Follow the M&A Money to Small- and Mid-Cap Cardiovascular Medtechs: Jason Mills (1/2/14) Some investors' eyes glaze over at the mention of medical devices. But it's time to wake up and focus on the stunning growth opportunities in small- and mid-cap cardiovascular medtech. Canaccord Genuity Managing Director Jason Mills covers companies on the front lines of innovation and in sectors where the trifecta of revenue, margins and reimbursement is achieving biotechlike levels. In this interview with The Life Sciences Report, Mills opens the new year with a discussion of the cardiovascular medtech industry and mentions companies that are probable acquisition candidates.
Deep Value Found in Small Medtech: Jason Mills (4/19/12) Medical device companies need to demonstrate four qualities to be good investment ideas, according to Senior Medical Devices Analyst and Managing Director Jason Mills of Canaccord Genuity. In this exclusive interview with The Life Sciences Report, Mills shares his precise criteria and pinpoints specific growth names that are trading at value levels.
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan Moreá>